Latest News

According to 5-year follow-up data, axicabtagene ciloleucel continues to demonstrate durable responses among patients with large B-cell lymphoma; however, late infections and subsequent malignant neoplasms showed the potential to develop and...

According to a phase 2 study, bintrafusp alfa demonstrated promising clinical activity among patients with recurrent or metastatic cervical cancer.

The US Food and Drug Administration approved axatilimab for the treatment of adult and pediatric patients with chronic graft-versus-host disease following a failure of at least 2 prior lines of systemic therapy.

Triple-negative myelofibrosis was found to be continually associated with decreased survival in addition to enhanced aggressive behavior with higher rates of leukemic transformation as well as a shorter duration of response to ruxolitinib,...

According to a phase 3 study, the addition of blinatumomab to consolidation chemotherapy for adult patients in measurable residual disease-negative remission from B-cell precursor acute lymphoblastic leukemia significantly improved overall...

Complete remission with partial hematological recovery as an efficacy end point was found to correlate with clinical benefits associated with clinically meaningful palliative effects for the treatment of patients with acute myeloid leukemia...

According to results from a phase 2 study, trastuzumab deruxtecan demonstrated promising activity among patients with HER2-expressing unresectable or recurrent biliary tract cancer.

According to results from the phase 2 NIFE study, nanoliposomal irinotecan with fluorouracil and leucovorin in the first-line setting demonstrated efficacy and safety among patients with advanced, unresectable cholangiocarcinoma.

Though the phase 2 MATCH trial was terminated early due to poor accrual, vemurafenib did appear to be tolerable and a potential treatment option among pediatric patients with tumors harboring BRAF-V600 mutations.

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.